Valiant Organics Grants 19,500 Employee Stock Options Under ESOP Scheme 2022

2 min read     Updated on 16 May 2026, 09:13 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Valiant Organics Limited's NRC approved the grant of 19,500 employee stock options on May 16, 2026, under the ESOP Scheme 2022, at an exercise price of Rs. 10/- per option. Each option is convertible into one equity share of face value Rs. 10/- each, exercisable within 3 years from the date of vesting. Of the total options, 15,000 will vest after a minimum vesting period of 1 year, while the remaining are subject to performance criteria. The grant complies with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, and was disclosed under Regulation 30 of SEBI LODR Regulations, 2015.

powered bylight_fuzz_icon
40491779

*this image is generated using AI for illustrative purposes only.

Valiant Organics Limited's Nomination and Remuneration Committee (NRC) of the Board of Directors convened on Saturday, May 16, 2026, and approved the grant of 19,500 (Nineteen Thousand Five Hundred) employee stock options to eligible employees under the Valiant Employees Stock Option Plan 2022 ("ESOP Scheme"). The grant has been made in compliance with the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company disclosed this development to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Details of the ESOP Grant

The following table summarises the key parameters of the stock option grant as disclosed in Annexure-I filed with the exchanges:

Parameter: Details
Total Options Granted: 19,500
Total Equity Shares Covered: 19,500
Exercise Price: Rs. 10/- per option
Face Value per Share: Rs. 10/- each
Conversion Ratio: 1 option = 1 equity share
Exercise Period: Within 3 years from date of vesting
Options Exercised: Nil
Options Lapsed: Nil
Money Realised by Exercise: Nil

Vesting Structure

The 19,500 options granted carry a structured vesting schedule as determined by the NRC. Of the total options granted, 15,000 options shall vest upon completion of a minimum vesting period of 1 year. The remaining options are subject to vesting upon achievement of specified performance criteria, as determined by the NRC in accordance with the applicable ESOP Scheme.

Once vested, each option entitles the holder to acquire one equity share of Valiant Organics upon payment of the exercise price. The exercise price shall in no event be less than the face value of the share, as prescribed under the scheme terms.

Scheme Administration and Compliance

The ESOP Scheme is administered by the NRC of the Board of Directors. The grant of options is based on eligibility criteria as defined under the scheme. The NRC determines the exercise price subject to conformity with applicable accounting policies. The scheme is in terms of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Key highlights of the scheme's governance framework include:

  • The NRC oversees administration and eligibility determination
  • Exercise price is set at Rs. 10/- per option, consistent with the face value
  • Diluted earnings per share pursuant to the issue of equity shares on exercise of options is not yet applicable, as options are yet to be exercised
  • No subsequent changes, cancellations, or variations to option terms have been reported

The intimation was signed by Kaustubh Kulkarni, Company Secretary (ICSI M. No: A52980), on behalf of Valiant Organics Limited.

Historical Stock Returns for Valiant Organics

1 Day5 Days1 Month6 Months1 Year5 Years
+4.44%-0.67%+12.36%+3.62%-9.26%-83.37%

How might the performance-based vesting criteria for the remaining 4,500 options impact employee retention and productivity at Valiant Organics over the next few years?

Given that the exercise price is set at face value (Rs. 10), significantly below the market price, what potential dilution effect could this have on existing shareholders when options are exercised?

Will Valiant Organics consider expanding its ESOP Scheme 2022 with additional grants to attract senior talent, and how might this affect the company's overall compensation strategy?

Valiant Organics Turns Profitable with ₹3,435.56 Lakh Net Profit in FY26

5 min read     Updated on 16 May 2026, 06:09 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Valiant Organics Limited announced its audited standalone and consolidated financial results for the year ended March 31, 2026, reporting a net profit of ₹3,435.56 lakh compared to a net loss of ₹299.84 lakh in the previous year. Revenue from operations increased to ₹73,838.31 lakh from ₹71,876.18 lakh, while total expenses decreased to ₹70,795.98 lakh. The Board identified the Pharma Business as an additional reportable segment alongside Specialty Chemicals, with the latter contributing ₹57,481.94 lakh and the former ₹16,356.38 lakh in revenue. The company also recognised ₹572.08 lakhs from a fire insurance claim settlement as exceptional items.

powered bylight_fuzz_icon
40479522

*this image is generated using AI for illustrative purposes only.

Valiant Organics Limited has reported its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company returned to profitability in FY26, recording a net profit of ₹3,435.56 lakh compared to a net loss of ₹299.84 lakh in the previous fiscal year. This turnaround was supported by revenue from operations, which increased to ₹73,838.31 lakh from ₹71,876.18 lakh in FY25.

For the quarter ended March 31, 2026, the net profit stood at ₹1,511.74 lakh, a significant rise from ₹395.62 lakh in the corresponding quarter of the previous year. Revenue for the quarter reached ₹21,770.02 lakh, up from ₹20,381.19 lakh in the same period last year. The Board identified the Pharma Business as an additional reportable segment alongside the existing Specialty Chemicals segment, in accordance with Ind AS 108.

Financial Performance

Total income for the year ended March 31, 2026, grew to ₹74,529.79 lakh from ₹72,701.54 lakh in the prior year. Total expenses decreased to ₹70,795.98 lakh from ₹72,460.55 lakh in the previous year. Profit before tax improved substantially to ₹4,305.89 lakh from ₹240.99 lakh. The statutory auditors, M/s. Gokhale & Sathe, issued an audit report with an un-modified opinion for the financial year ended March 31, 2026.

Standalone Financial Results

The table below summarises the key standalone financial metrics for the year ended March 31, 2026:

Particulars Year Ended 31-Mar-2026 (₹ in Lakhs) Year Ended 31-Mar-2025 (₹ in Lakhs)
Revenue from Operations 73,838.31 71,876.18
Total Income 74,529.79 72,701.54
Total Expenses 70,795.98 72,460.55
Profit Before Tax 4,305.89 240.99
Net Profit / (Loss) 3,435.56 (299.84)
Basic EPS (₹) 12.27 (1.09)

Segment Reporting

Based on internal reports, the Board approved the identification of the Pharma Business as an additional reportable segment. For the year ended March 31, 2026, the Specialty Chemical Division reported revenue of ₹57,481.94 lakh, while the newly identified Pharma Division reported revenue of ₹16,356.38 lakh. The company also received ₹852.76 lakhs towards a fire insurance claim settlement during the year, with ₹572.08 lakhs recognised under exceptional items.

Historical Stock Returns for Valiant Organics

1 Day5 Days1 Month6 Months1 Year5 Years
+4.44%-0.67%+12.36%+3.62%-9.26%-83.37%

Given the Pharma Division's narrowing losses from ₹3,532.95 lakh to ₹471.34 lakh, what timeline can investors expect for the segment to achieve breakeven or profitability, and which product categories are likely to drive that turnaround?

With Dhanvallabh Ventures LLP newly classified as a Material Subsidiary for FY 2026-27, how might its operations and capital requirements impact Valiant Organics' consolidated financial position and group strategy going forward?

How could the Conducting cum Loan & License Agreement with Aarti Pharmalabs Ltd for the AJ4 division affect Valiant Organics' revenue mix, margin profile, and related-party transaction disclosures in FY27?

More News on Valiant Organics

1 Year Returns:-9.26%